Menu
Search
|

Menu

Close
X

Zogenix Inc ZGNX.OQ (NASDAQ Stock Exchange Global Market)

41.25 USD
-0.10 (-0.24%)
As of Feb 16
chart
Previous Close 41.35
Open 41.45
Volume 226,666
3m Avg Volume 205,117
Today’s High 42.45
Today’s Low 40.65
52 Week High 43.35
52 Week Low 8.55
Shares Outstanding (mil) 31.54
Market Capitalization (mil) 1,207.95
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.43 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
10
FY16
29
FY15
27
EPS (USD)
FY17
-1.756
FY16
-2.771
FY15
-1.932
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
44.12
5.77
Price to Book (MRQ)
vs sector
11.97
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
28.43
16.52
LT Debt to Equity (MRQ)
vs sector
19.82
12.22
Return on Investment (TTM)
vs sector
-39.41
14.43
Return on Equity (TTM)
vs sector
-70.89
16.13

EXECUTIVE LEADERSHIP

Cam Garner
Independent Chairman of the Board, Since 2006
Salary: --
Bonus: --
Stephen Farr
President, Chief Executive Officer, Director, Since 2015
Salary: $387,544.00
Bonus: $200,000.00
Michael Smith
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Gail Farfel
Executive Vice President, Chief Development Officer, Since 2015
Salary: --
Bonus: --
Bradley Galer
Executive Vice President and Chief Medical Officer, Since 2013
Salary: $346,250.00
Bonus: $145,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5858 Horton St Ste 455
EMERYVILLE   CA   94608-2072

Phone: +1510.5508300

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

SPONSORED STORIES